These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 31265867)

  • 41. In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm.
    Gómez-Junyent J; Murillo O; Yu HH; Azad MAK; Wickremasinghe H; Rigo-Bonnin R; Benavent E; Ariza J; Li J
    Int J Antimicrob Agents; 2021 Feb; 57(2):106246. PubMed ID: 33253904
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effective removal of colistin methanesulphonate and formed colistin during intermittent haemodialysis in a patient infected by polymyxin-only-susceptible Pseudomonas aeruginosa.
    Luque S; Sorli L; Li J; Collado S; Barbosa F; Berenguer N; Horcajada JP; Grau S
    J Chemother; 2014 Apr; 26(2):122-4. PubMed ID: 24090909
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections.
    Hengzhuang W; Green K; Pressler T; Skov M; Katzenstein TL; Wu X; Høiby N
    Pediatr Pulmonol; 2019 May; 54(5):575-580. PubMed ID: 30803159
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Shedding light on the use of colistin: still gaps to be filled].
    Luque S; Grau S; Berenguer N; Horcajada JP; Sorlí L; Montero MM; Salas E
    Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):287-96. PubMed ID: 21440335
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
    Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.
    Imberti R; Cusato M; Villani P; Carnevale L; Iotti GA; Langer M; Regazzi M
    Chest; 2010 Dec; 138(6):1333-9. PubMed ID: 20558557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Community-acquired Pseudomonas aeruginosa urinary tract infections in children hospitalized in a tertiary center: relative frequency, risk factors, antimicrobial resistance and treatment.
    Marcus N; Ashkenazi S; Samra Z; Cohen A; Livni G
    Infection; 2008 Oct; 36(5):421-6. PubMed ID: 18795227
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of multidrug-resistant pseudomonas aeruginosa using extended-infusion antimicrobial regimens.
    Heil EL; Lowery AV; Thom KA; Nicolau DP
    Pharmacotherapy; 2015 Jan; 35(1):54-8. PubMed ID: 25556715
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?
    Bergen PJ; Landersdorfer CB; Zhang J; Zhao M; Lee HJ; Nation RL; Li J
    Diagn Microbiol Infect Dis; 2012 Nov; 74(3):213-23. PubMed ID: 22959816
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Urinary neutrophil gelatinase-associated lipocalin for early detection of acute kidney injury in geriatric patients with urinary tract infection treated by colistin.
    Shavit L; Manilov R; Wiener-Well Y; Algur N; Slotki I
    Clin Nephrol; 2013 Dec; 80(6):405-16. PubMed ID: 24120670
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.
    Aoki N; Tateda K; Kikuchi Y; Kimura S; Miyazaki C; Ishii Y; Tanabe Y; Gejyo F; Yamaguchi K
    J Antimicrob Chemother; 2009 Mar; 63(3):534-42. PubMed ID: 19147523
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
    Sader HS; Huband MD; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
    [No Abstract]   [Full Text] [Related]  

  • 54. Efficacy of meropenem extended infusion vs intermittent bolus monotherapy and in combination with colistin against Pseudomonas aeruginosa biofilm.
    Benavent E; Ulldemolins M; El Haj C; Rigo-Bonnin R; Yu H; Wang L; Wickremasinghe H; Ariza J; Murillo O
    Int J Antimicrob Agents; 2023 Aug; 62(2):106856. PubMed ID: 37211260
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study.
    Rocco M; Montini L; Alessandri E; Venditti M; Laderchi A; De Pascale G; Raponi G; Vitale M; Pietropaoli P; Antonelli M
    Crit Care; 2013 Aug; 17(4):R174. PubMed ID: 23945197
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
    García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva D; Chaves C; Pássaro L; Paixão L; Cantón R;
    Int J Antimicrob Agents; 2020 Mar; 55(3):105887. PubMed ID: 31926283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antimicrobial susceptibilities and clinical characterization of Pseudomonas aeruginosa isolates from urinary tract infections.
    Zhang X; Niu S; Zhang L
    Urol Int; 2014; 93(4):464-9. PubMed ID: 24642393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multiple resistant Pseudomonas aeruginosa in contemporary medical practice: findings from urinary isolates at a Nigerian University Teaching Hospital.
    Jombo GT; Jonah P; Ayeni JA
    Niger J Physiol Sci; 2008; 23(1-2):105-9. PubMed ID: 19434224
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa.
    Lu Q; Girardi C; Zhang M; Bouhemad B; Louchahi K; Petitjean O; Wallet F; Becquemin MH; Le Naour G; Marquette CH; Rouby JJ
    Intensive Care Med; 2010 Jul; 36(7):1147-55. PubMed ID: 20397007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.
    Xipell M; Paredes S; Fresco L; Bodro M; Marco F; Martínez JA; Soriano A
    J Glob Antimicrob Resist; 2018 Jun; 13():165-170. PubMed ID: 29366723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.